Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Richard K. Valicenti"'
Autor:
Edouard J. Trabulsi, Timothy N. Showalter, Patricia Dugan, Costas D. Lallas, Peter McCue, Jaspreet Singh, Adam P. Dicker, Fran Guiles, Richard K. Valicenti, Jean H. Hoffman-Censits, Jianqing Lin, Leonard G. Gomella
Publikováno v:
Journal of Oncology Practice. 6:e5-e10
To report on the 15-year prostate cancer experience of our multidisciplinary genitourinary cancer clinic established in 1996 at the National Cancer Institute (NCI) -designated Jefferson Kimmel Cancer Center. Patients with genitourinary cancers were e
Autor:
Colleen A. Lawton, Joycelyn L. Speight, P. Rubin, Kyounghwa Bae, Richard K. Valicenti, David J. Grignon, Mack Roach, R. Jeffrey Lee, Miljenko V. Pilepich, Harvey B. Wolkov
Publikováno v:
Journal of Clinical Oncology. 26:585-591
Purpose Radiation Therapy Oncology Group (RTOG) 8610 was the first phase III randomized trial to evaluate neoadjuvant androgen deprivation therapy (ADT) in combination with external-beam radiotherapy (EBRT) in men with locally advanced prostate cance
Autor:
Jeffrey D. Forman, Kevin M. Slawin, Howard M. Sandler, Larry L. Kestin, Jeff M. Michalski, Mitchell S. Anscher, Stanley L. Liauw, Michael W. Kattan, Alan Pollack, Eric A. Klein, Michael J. Zelefsky, Andrew J. Stephenson, Deborah A. Kuban, Charles Catton, Daniel W. Lin, Richard K. Valicenti, Peter T. Scardino, Theodore L. DeWeese, Thomas M. Pisansky, Claus G. Roehrborn
Publikováno v:
Journal of Clinical Oncology. 25:2035-2041
Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies
Autor:
M. DeSilvio, Charles R. Thomas, M. Rotman, Sucha O. Asbell, Seunggu J. Han, Richard K. Valicenti, C. Lawton, Mitchell Machtay, Valery Uhl, Mack Roach, M. J. Seider, W. S. Shipley, C. Jones
Publikováno v:
Journal of Clinical Oncology. 21:1904-1911
Purpose: This trial tested the hypothesis that combined androgen suppression (CAS) and whole-pelvic (WP) radiotherapy (RT) followed by a boost to the prostate improves progression-free survival (PFS) by 10% compared with CAS and prostate-only (PO) RT
Autor:
H.M. Sandler, Richard K. Valicenti, Harmar D. Brereton, Arthur T. Porter, Michelle DeSilvio, Gerald E. Hanks, William U. Shipley
Publikováno v:
Journal of Clinical Oncology. 23:4549-4549
4549 Background: A requirement of a surrogate endpoint for prostate cancer-specific survival (PCSS) is its validation for a cohort of prospectively treated patients. We applied Prentice’s criteria to determine if prostate-specific antigen doubling